Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 21, 2026

GM releases 2026 second-quarter results, raises full-year 2026 guidance and declares quarterly dividend

View original at finance.yahoo.com
GM releases 2026 second-quarter results, raises full-year 2026 guidance and declares quarterly dividend DETROIT, July 21, 2026 /PRNewswire/ -- General Motors (NYSE: GM) today reported second-quarter 2026 revenue of $48.0 billion, net income attributable to stockholders of $1.3 billion, and EBIT-adjusted of $3.9 billion…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • GM is raising its full-year 2026 EBIT-adjusted guidance for the second time this year.

    60% confidence

  • GM's Board of Directors declared a quarterly cash dividend of $0.18 per share, payable September 17, 2026, to holders of record as of September 4, 2026.

    60% confidence

  • GM expects full-year 2026 net income attributable to stockholders of $8.4 billion to $9.8 billion, automotive operating cash flow of $15.4 billion to $19.4 billion, and EPS-diluted of $8.98 to $10.98.

    60% confidence

  • These expected full-year 2026 financial results do not include the potential impact of future adjustments related to special items.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
GM releases 2026 second-quarter results, raises full-year 2026 guidance and declares quarterly dividend — Source | Via News | ViaNews Market